Get the Stockscreener App
118.17
0.19%
-0.22
After Hours:
120.00
1.83
+1.55%
Biogen Inc stock is traded at $118.17, with a volume of 1.31M.
It is down -0.19% in the last 24 hours and down -1.93% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$118.39
Open:
$118.75
24h Volume:
1.31M
Relative Volume:
0.79
Market Cap:
$18.10B
Revenue:
$9.61B
Net Income/Loss:
$1.62B
P/E Ratio:
10.67
EPS:
11.07
Net Cash Flow:
$1.77B
1W Performance:
-4.34%
1M Performance:
-1.93%
6M Performance:
-31.71%
1Y Performance:
-46.95%
1-Day Range:
$118.05
$120.11
1-Week Range:
$115.25
$123.53
52-Week Range:
$110.03
$238.00
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
118.17 | 18.10B | 9.61B | 1.62B | 1.77B | 11.07 |
|
LLY
Lilly Eli Co
|
734.57 | 739.39B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.22 | 375.64B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
184.60 | 351.09B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
65.77 | 307.32B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
NVS
Novartis Ag Adr
|
108.70 | 225.73B | 53.22B | 12.86B | 14.85B | 6.39 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Bokf Na - MarketBeat
Brevan Howard Capital Management LP Purchases 6,064 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
BIIB Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm - ACCESS Newswire
UPCOMING BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Axa S.A. Increases Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Spinal Muscular Atrophy Market Advances with Gene Therapies and Rare Disease Research | Novartis, Biogen, Roche - openPR.com
South San Francisco to Host Biogen’s New West Coast Operations - whatnow.com
Navigating the Trump tariffs, part two: Amgen, Biogen, others - BioWorld MedTech
Biogen (NASDAQ:BIIB) Given New $169.00 Price Target at Mizuho - MarketBeat
Biogen Says Its US Manufacturing Will Limit Tariff Impacts - MSN
BIOGEN INC. (NASDAQ:BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc. (NASDAQ: BIIB) - ACCESS Newswire
Analysts Set Biogen Inc. (NASDAQ:BIIB) Price Target at $195.85 - MarketBeat
Wedbush Predicts Biogen's Q4 Earnings (NASDAQ:BIIB) - MarketBeat
Leerink Partnrs Has Strong Estimate for Biogen Q3 Earnings - MarketBeat
Gene Giant Biogen to Open West Coast Hub in South SF - The Real Deal
Digital Biomarkers Market Hits New High | Major Giants Biogen, Apple, Alphabet, Evidation Health, Koneksa - openPR.com
Medisafe PATHWAYS, Eisai and Biogen Recognized for - GlobeNewswire
Medisafe PATHWAYS, Eisai and Biogen Recognized for Alzheimer’s Disease Innovation in 2025 MedTech Breakthrough Awards Program - GlobeNewswire Inc.
Form 424B2 BIOGEN INC. - StreetInsider
Comerica Bank Sells 5,735 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Stifel Financial Corp Reduces Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (NASDAQ:BIIB) Announces Quarterly Earnings Results, Misses Expectations By $0.24 EPS - MarketBeat
Northern Trust Corp Grows Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
After big acquisition, Biogen looks to set up West Coast hub in South San Francisco - The Business Journals
Biogen (NasdaqGS:BIIB) Selects Multiple Co-Lead Underwriters for US$1 Billion Fixed-Income Offering - simplywall.st
Biogen (NASDAQ:BIIB) Price Target Lowered to $175.00 at JPMorgan Chase & Co. - MarketBeat
Biogen (BIIB) Price Target Lowered by Mizuho Despite Outperform Rating | BIIB Stock News - GuruFocus
Biogen (BIIB) Prepares for Mid-2026 Readout of Key Program | BIIB Stock News - GuruFocus
Biogen Inc. (NASDAQ:BIIB) Shares Bought by Brown Advisory Inc. - MarketBeat
Biogen (BIIB) Receives Price Target Reduction from Mizuho | BIIB Stock News - GuruFocus
HC Wainwright Lowers Biogen (NASDAQ:BIIB) Price Target to $187.00 - MarketBeat
AQR Capital Management LLC Purchases 489,811 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
FY2025 Earnings Estimate for Biogen Issued By William Blair - MarketBeat
Lido Advisors LLC Acquires 39,910 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Schonfeld Strategic Advisors LLC Increases Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (BIIB): JP Morgan Lowers Price Target But Maintains Neutral Rating | BIIB Stock News - GuruFocus
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Spinocerebellar Ataxias Pipeline 2025: Comprehensive - openPR.com
JPMorgan Adjusts Price Target for Biogen (BIIB) Following Q1 Report | BIIB Stock News - GuruFocus
Oligonucleotide Delivery System Market Key Players Analysis - openPR.com
Red Biotechnology Market to Witness Remarkable Growth with - openPR.com
Integrated Wealth Concepts LLC Has $685,000 Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
PDT Partners LLC Purchases 22,908 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Voya Investment Management LLC Decreases Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen's (BIIB) Hold Rating Reaffirmed at Needham & Company LLC - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Position Trimmed by MML Investors Services LLC - MarketBeat
Biogen First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Q1 2025 Earnings Call Transcript - Insider Monkey
Quarry LP Buys Shares of 3,005 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (BIIB) Maintains Outperform Rating Despite Lowered Price Target | BIIB Stock News - GuruFocus
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):